| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Over the last 12 months, insiders at Milestone Pharmaceuticals Inc. have bought $0 and sold $0 worth of Milestone Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Milestone Pharmaceuticals Inc. have bought $6.96M and sold $8.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,000 shares for transaction amount of $32,830 was made by Bharucha David (Chief Medical Officer) on 2022‑12‑05.
| 2022-12-05 | Bharucha David | Chief Medical Officer | 7,000 0.0162% | $4.69 | $32,830 | -27.58% | ||
| 2022-12-01 | Bharucha David | Chief Medical Officer | 3,000 0.007% | $4.86 | $14,580 | -29.01% | ||
| 2022-10-21 | Liebert Debra K. | director | 4,000 0.0096% | $5.26 | $21,040 | -28.77% | ||
| 2022-10-20 | Pasternak Richard C | director | 10,000 0.0232% | $5.20 | $52,000 | -30.21% | ||
| 2022-10-20 | Liebert Debra K. | director | 10,000 0.0236% | $5.29 | $52,900 | -30.21% | ||
| 2022-10-19 | Wills Robert James | director | 15,000 0.0349% | $4.93 | $73,950 | -26.41% | ||
| 2022-10-19 | TOMSICEK MICHAEL JOHN | director | 15,000 0.0376% | $5.32 | $79,800 | -26.41% | ||
| 2022-09-07 | Sale | WONG RODERICK | 1.56M 3.6651% | $8.71 | $13.56M | -56.03% | ||
| 2022-09-07 | WONG RODERICK | 1.56M 3.6651% | $8.71 | $13.56M | -56.03% | |||
| 2022-05-31 | TRUEX PAUL F | 5,000 0.0118% | $5.60 | $28,000 | -19.25% | |||
| 2020-07-29 | Sale | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10 percent owner | 500,000 1.5968% | $8.32 | $4.16M | -22.80% | |
| 2020-07-28 | Sale | FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10 percent owner | 19,863 0.0675% | $8.10 | $160,890 | -15.61% | |
| 2020-03-19 | RTW INVESTMENTS, LP | 10 percent owner | 5,870 0.02% | $10.87 | $63,804 | -47.34% | ||
| 2020-03-18 | RTW INVESTMENTS, LP | 10 percent owner | 2,705 0.0091% | $10.36 | $28,029 | -45.49% | ||
| 2020-03-02 | RTW INVESTMENTS, LP | 10 percent owner | 78,263 0.3217% | $18.95 | $1.48M | -63.55% | ||
| 2020-01-13 | RTW INVESTMENTS, LP | 10 percent owner | 270,000 1.0575% | $16.25 | $4.39M | -59.47% | ||
| 2019-12-31 | RTW INVESTMENTS, LP | director | 21,438 0.0846% | $15.50 | $332,340 | -56.84% | ||
| 2019-12-30 | RTW INVESTMENTS, LP | director | 1,333 0.0054% | $15.48 | $20,638 | -55.51% | ||
| 2019-11-25 | Sale | Novo Holdings A/S | 10 percent owner | 240,000 0.8778% | $16.00 | $3.84M | -57.86% | |
| 2019-11-20 | RTW INVESTMENTS, LP | 10 percent owner | 400,000 1.4001% | $16.00 | $6.4M | -58.59% |
| RTW INVESTMENTS, LP | 10 percent owner | 4315102 8.071% | $7.21M | 13 | 0 | |
| WONG RODERICK | 4315102 8.071% | $7.21M | 1 | 1 | <0.0001% | |
| Novo Holdings A/S | 10 percent owner | 2434470 4.5534% | $4.07M | 1 | 1 | |
| BDC CAPITAL INC. | 10 percent owner | 2388088 4.4667% | $3.99M | 1 | 0 | |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC | 10 percent owner | 2254920 4.2176% | $3.77M | 1 | 2 | |
| TRUEX PAUL F | 81780 0.153% | $136,572.60 | 1 | 0 | <0.0001% | |
| TOMSICEK MICHAEL JOHN | director | 15000 0.0281% | $25,050.00 | 1 | 0 | <0.0001% |
| Wills Robert James | director | 15000 0.0281% | $25,050.00 | 1 | 0 | <0.0001% |
| Pasternak Richard C | director | 10000 0.0187% | $16,700.00 | 1 | 0 | <0.0001% |
| Bharucha David | Chief Medical Officer | 10000 0.0187% | $16,700.00 | 2 | 0 | <0.0001% |
| Liebert Debra K. | director | 4000 0.0075% | $6,680.00 | 2 | 0 | <0.0001% |
$30,470,407 | 140 | 20.39% | $100M | |
$2,621,791 | 113 | 12.01% | $87.94M | |
$16,259,194 | 41 | 120.51% | $89.27M | |
$7,147,964 | 34 | 24.78% | $86.19M | |
$64,487,106 | 32 | -22.92% | $94.45M | |
$36,079,815 | 31 | 43.23% | $85.83M | |
$1,129,899 | 27 | 1.18% | $82.24M | |
$38,821,584 | 20 | -2.17% | $95.9M | |
$17,594,514 | 16 | -20.37% | $92.11M | |
$277,862 | 15 | 59.79% | $92.72M | |
$14,562,799 | 14 | -4.77% | $82.56M | |
Milestone Pharmaceuticals Inc. (MIST) | $13,919,584 | 9 | -30.43% | $89.29M |
$91,549,696 | 8 | -6.55% | $85.42M | |
$99,355,998 | 7 | -65.74% | $83.59M | |
$272,982 | 6 | -28.53% | $93.3M | |
$401,951 | 4 | 57.41% | $90.85M | |
$4,256,958 | 4 | 22.95% | $83.46M | |
$4,030 | 1 | 9.14% | $90.57M | |
$3,620 | 1 | 94.16% | $96.84M |
| Increased Positions | 21 | +30% | 3M | +11.85% |
| Decreased Positions | 28 | -40% | 16M | -62.99% |
| New Positions | 15 | New | 3M | New |
| Sold Out Positions | 17 | Sold Out | 10M | Sold Out |
| Total Postitions | 63 | -10% | 12M | -51.14% |
| Millennium Management Llc | $3,541.00 | 5.1% | 2.7M | -75,266 | -2.71% | 2024-12-31 |
| Alta Fundamental Advisers Llc | $3,483.00 | 5.02% | 2.66M | 0 | 0% | 2024-12-31 |
| Rtw Investments, Lp | $3,283.00 | 4.73% | 2.51M | -750,000 | -23.03% | 2024-12-31 |
| Orbimed Advisors Llc | $2,620.00 | 3.77% | 2M | 0 | 0% | 2024-12-31 |
| Nantahala Capital Management, Llc | $1,893.00 | 2.73% | 1.45M | -304,736 | -17.41% | 2024-12-31 |
| Bleichroeder Lp | $1,737.00 | 2.5% | 1.33M | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $1,689.00 | 2.43% | 1.29M | +370,829 | +40.38% | 2024-12-31 |
| Bml Capital Management, Llc | $1,488.00 | 2.14% | 1.14M | 0 | 0% | 2024-12-31 |
| Lion Point Capital, Lp | $1,344.00 | 1.94% | 1.03M | -628,348 | -37.99% | 2024-12-31 |
| Goldman Sachs Group Inc | $1,235.00 | 1.78% | 942,407 | -410,660 | -30.35% | 2024-12-31 |